Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma

Yong Park, Dae Sik Kim, Min Ji Jeon, Byung Hyun Lee, Eun Sang Yu, Ka Won Kang, Se Ryeon Lee, Hwa Jung Sung, Myung-Hyun Nam, Soo-Young Yoon, Chul Won Choi, Eun Suk Kang, Duck Cho, Kihyun Kim, Byung Soo Kim, Dae Won Kim, Seok Jin Kim

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Background: Single-dose etoposide was used an outpatient-based protocol for mobilization in patients with multiple myeloma (MM) for autologous stem cell transplantation (ASCT). Thus, we retrospectively analyzed the efficacy and safety of our one-day protocol in comparison with that of previous methods. Methods: We retrospectively analyzed 168 patients with MM who underwent peripheral blood stem cell collection for upfront ASCT between 2008 and 2018. The mobilization protocols included G-CSF alone (G-mobilization), one-day 375 mg/m2 of etoposide (E375), two-days of 375 mg/m2 of etoposide (E750), or one-day high-dose (3.5 g/m2) cyclophosphamide (HD CY). For comparison of efficacy of each protocol, collected CD34+ cells over 4 × 106/kg and under 2 × 106/kg were defined as “adequate harvest” and “harvest failure,” respectively. Results: The median number of collected CD34+ cells was 5.58 × 106/kg in patients receiving single-dose etoposide, and the percentage of uncomplicated optimal harvest of E375 (65.6%, 21/32) was significantly higher than that of E750 (41.9%, 13/31) and HD CY (31.3%, 15/48). The E375 showed the highest rate of adequate harvest (96.9%, 31/32) compared to that of E750 (87.1%), HD CY (75.0%), and G-mobilization (59.6%). Most E375 patients achieved adequate harvest without complication (29/32, 90.6%), the CD34+ cell collection yield on apheresis days one and two of E375 was not significantly different from that of E750, and no harvest failures occurred for E375. Neutrophil and platelet engraftments were significantly faster in E375 than other groups (P <.001). Conclusions: The use of single-dose etoposide could be an effective and safe method for mobilization in patients with MM.

Original languageEnglish
Pages (from-to)579-588
Number of pages10
JournalJournal of Clinical Apheresis
Issue number5
Publication statusPublished - 2019 Oct 1


  • autologous stem cell transplantation
  • etoposide
  • mobilization
  • multiple myeloma

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma'. Together they form a unique fingerprint.

Cite this